Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring

Reuters06-20

Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring

Nkgen Biotech Inc. has made significant progress in its acquisition of NKMAX Co., Ltd., following the Seoul Bankruptcy Court's approval of a Conditional Investment Agreement. The company was announced as the final preferred bidder for a majority stake in NKMAX, pending stakeholder approval. On June 18, 2025, stakeholders of NKMAX approved the agreement, fulfilling all necessary conditions for the acquisition. The completion of this acquisition is anticipated in early August 2025. NKMAX, a clinical-stage biotechnology firm based in Seoul, specializes in immune cell therapies and has been undergoing rehabilitation efforts, with its trading on the KOSDAQ currently suspended.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-055833), on June 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2544247371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544247371","market":"us","top_or_hot":-1,"title":"Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nkgen Biotech Inc. has made significant progress in its acquisition of NKMAX Co., Ltd., following the Seoul Bankruptcy Court's approval of a Conditional Investment Agreement. The company was announced as the final preferred bidder for a majority stake in NKMAX, pending stakeholder approval. On June 18, 2025, stakeholders of NKMAX approved the agreement, fulfilling all necessary conditions for the acquisition. The completion of this acquisition is anticipated in early August 2025. NKMAX, a clinical-stage biotechnology firm based in Seoul, specializes in immune cell therapies and has been undergoing rehabilitation efforts, with its trading on the KOSDAQ currently suspended.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-055833), on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nkgen Biotech Inc. has made significant progress in its acquisition of NKMAX Co., Ltd., following the Seoul Bankruptcy Court's approval of a Conditional Investment Agreement. The company was announced as the final preferred bidder for a majority stake in NKMAX, pending stakeholder approval. On June 18, 2025, stakeholders of NKMAX approved the agreement, fulfilling all necessary conditions for the acquisition. The completion of this acquisition is anticipated in early August 2025. NKMAX, a clinical-stage biotechnology firm based in Seoul, specializes in immune cell therapies and has been undergoing rehabilitation efforts, with its trading on the KOSDAQ currently suspended.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-055833), on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKGN","symbol_name":"NKGen Biotech Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL9MT7d:1","article_id":"2544247371","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544247371","pubTimestamp":1750420844,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nkgen Biotech Inc. has made significant progress in its acquisition of NKMAX Co., Ltd., following the Seoul Bankruptcy Court's approval of a Conditional Investment Agreement. The company was announced as the final preferred bidder for a majority stake in NKMAX, pending stakeholder approval. On June 18, 2025, stakeholders of NKMAX approved the agreement, fulfilling all necessary conditions for the acquisition. The completion of this acquisition is anticipated in early August 2025. NKMAX, a clinical-stage biotechnology firm based in Seoul, specializes in immune cell therapies and has been undergoing rehabilitation efforts, with its trading on the KOSDAQ currently suspended.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKGN":"NKGen Biotech Inc.","BK4139":"生物科技"},"translate_title":"Nkgen Biotech Inc.在破产重组中获得利益相关者批准后准备完成对NKMAX的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKGN":0.9},"content_text":"Nkgen Biotech Inc. Poised to Finalize Acquisition of NKMAX Following Stakeholder Approval Amid Bankruptcy Restructuring\n    \n\n        Nkgen Biotech Inc. has made significant progress in its acquisition of NKMAX Co., Ltd., following the Seoul Bankruptcy Court's approval of a Conditional Investment Agreement. The company was announced as the final preferred bidder for a majority stake in NKMAX, pending stakeholder approval. On June 18, 2025, stakeholders of NKMAX approved the agreement, fulfilling all necessary conditions for the acquisition. The completion of this acquisition is anticipated in early August 2025. NKMAX, a clinical-stage biotechnology firm based in Seoul, specializes in immune cell therapies and has been undergoing rehabilitation efforts, with its trading on the KOSDAQ currently suspended.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-055833), on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544247371","isCrawlerRequest":true}